Scott D Grosse1, Robert J Berry2, J Mick Tilford3, James E Kucik4, Norman J Waitzman5. 1. National Center on Birth Defects and Developmental Disabilities, CDC, Atlanta, Georgia. Electronic address: sgrosse@cdc.gov. 2. National Center on Birth Defects and Developmental Disabilities, CDC, Atlanta, Georgia. 3. Department of Health Policy and Management, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas. 4. Office of the Associate Director for Policy, CDC, Atlanta, Georgia. 5. Department of Economics, University of Utah, Salt Lake City, Utah.
Abstract
INTRODUCTION: Although fortification of food with folic acid has been calculated to be cost saving in the U.S., updated estimates are needed. This analysis calculates new estimates from the societal perspective of net cost savings per year associated with mandatory folic acid fortification of enriched cereal grain products in the U.S. that was implemented during 1997-1998. METHODS: Estimates of annual numbers of live-born spina bifida cases in 1995-1996 relative to 1999-2011 based on birth defects surveillance data were combined during 2015 with published estimates of the present value of lifetime direct costs updated in 2014 U.S. dollars for a live-born infant with spina bifida to estimate avoided direct costs and net cost savings. RESULTS: The fortification mandate is estimated to have reduced the annual number of U.S. live-born spina bifida cases by 767, with a lower-bound estimate of 614. The present value of mean direct lifetime cost per infant with spina bifida is estimated to be $791,900, or $577,000 excluding caregiving costs. Using a best estimate of numbers of avoided live-born spina bifida cases, fortification is estimated to reduce the present value of total direct costs for each year's birth cohort by $603 million more than the cost of fortification. A lower-bound estimate of cost savings using conservative assumptions, including the upper-bound estimate of fortification cost, is $299 million. CONCLUSIONS: The estimates of cost savings are larger than previously reported, even using conservative assumptions. The analysis can also inform assessments of folic acid fortification in other countries. Published by Elsevier Inc.
INTRODUCTION: Although fortification of food with folic acid has been calculated to be cost saving in the U.S., updated estimates are needed. This analysis calculates new estimates from the societal perspective of net cost savings per year associated with mandatory folic acid fortification of enriched cereal grain products in the U.S. that was implemented during 1997-1998. METHODS: Estimates of annual numbers of live-born spina bifida cases in 1995-1996 relative to 1999-2011 based on birth defects surveillance data were combined during 2015 with published estimates of the present value of lifetime direct costs updated in 2014 U.S. dollars for a live-born infant with spina bifida to estimate avoided direct costs and net cost savings. RESULTS: The fortification mandate is estimated to have reduced the annual number of U.S. live-born spina bifida cases by 767, with a lower-bound estimate of 614. The present value of mean direct lifetime cost per infant with spina bifida is estimated to be $791,900, or $577,000 excluding caregiving costs. Using a best estimate of numbers of avoided live-born spina bifida cases, fortification is estimated to reduce the present value of total direct costs for each year's birth cohort by $603 million more than the cost of fortification. A lower-bound estimate of cost savings using conservative assumptions, including the upper-bound estimate of fortification cost, is $299 million. CONCLUSIONS: The estimates of cost savings are larger than previously reported, even using conservative assumptions. The analysis can also inform assessments of folic acid fortification in other countries. Published by Elsevier Inc.
Authors: Christine M Pfeiffer; Jeffery P Hughes; David A Lacher; Regan L Bailey; R J Berry; Mindy Zhang; Elizabeth A Yetley; Jeanne I Rader; Christopher T Sempos; Clifford L Johnson Journal: J Nutr Date: 2012-03-21 Impact factor: 4.798
Authors: Mark A Canfield; Julianne S Collins; Lorenzo D Botto; Laura J Williams; Cara T Mai; Russell S Kirby; Kay Pearson; Owen Devine; Joe Mulinare Journal: Birth Defects Res A Clin Mol Teratol Date: 2005-10
Authors: Sarah C Tinker; Owen Devine; Cara Mai; Heather C Hamner; Jennita Reefhuis; Suzanne M Gilboa; Nicole F Dowling; Margaret A Honein Journal: Birth Defects Res A Clin Mol Teratol Date: 2013-10
Authors: Adrian Caceres; Jeffrey P Blount; Martina Messing-Jünger; Sandip Chatterjee; Graham Fieggen; Jose Francisco Salomao Journal: Childs Nerv Syst Date: 2021-05-03 Impact factor: 1.475
Authors: Brian M Inouye; Ruiyang Jiang; M Hassan Alkazemi; Hsin-Hsiao S Wang; Steven Wolf; Gina-Maria Pomann; Rohit Tejwani; John S Wiener; J Todd Purves; Jonathan C Routh Journal: Disabil Health J Date: 2019-01-21 Impact factor: 2.554
Authors: Cristina Carias; Harrell W Chesson; Scott D Grosse; Rui Li; Martin I Meltzer; Gabrielle F Miller; Louise B Murphy; Tursynbek A Nurmagambetov; Jamison J Pike; Hilary K Whitham Journal: Am J Prev Med Date: 2018-01-12 Impact factor: 5.043
Authors: Daniel J Kim; Arvind Venkataraman; Priyanka Caroline Jain; Eleanor P Wiesler; Melody DeBlasio; Jonathan Klein; Stephanie S Tu; Seohyuk Lee; Ruslan Medzhitov; Akiko Iwasaki Journal: Proc Natl Acad Sci U S A Date: 2020-06-22 Impact factor: 11.205